Two years in, the team at Nous­Com bags $49M to fund first hu­man stud­ies of neoanti­gen drugs

As Nous­Com CEO Al­fre­do Nicosia likes to say, the Basel-based biotech is a rel­a­tive fledg­ling at 2-years of age. But the core re­search team there …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.